To evaluate the efficacy and safety of a single preoperative intravenous dose of tranexamic acid (TXA) during sleeve gastrectomy (SG), focusing on intraoperative bleeding and postoperative complications.
Key Findings:
TXA significantly reduces intraoperative bleeding and hemoglobin decline without increasing complications (p-value < 0.05).
No thromboembolic events were reported, addressing safety concerns.
TXA approximately halves the odds of postoperative bleeding and shortens operative duration and hospitalization.
Interpretation:
The study supports the use of TXA in sleeve gastrectomy as it effectively reduces bleeding and does not increase the risk of thromboembolic complications, suggesting a shift in clinical practice.
Limitations:
Heterogeneity in dosing, timing, and administration of TXA across studies.
Most trials are single center with modest sample sizes, which may limit generalizability.
Further multicenter studies are needed to confirm findings and define optimal TXA regimens.
Conclusion:
TXA is a promising adjunct in sleeve gastrectomy that enhances safety and efficacy, warranting broader adoption in metabolic and bariatric surgery, while further research is needed to solidify these findings.
